Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases

Melissa Amy Magliocco; Alice Bendix Gottlieb

doi:10.1016/j.jaad.2004.05.013

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases

Melissa Amy Magliocco, Alice Bendix Gottlieb

Research output: Contribution to journal › Article › peer-review

101 Scopus citations

Abstract

Psoriasis and psoriatic arthritis are exacerbated by interferon alfa and other treatments for hepatitis C virus infection. Immunosuppressants and hepatotoxic drugs are relatively contraindicated in hepatitis C. Data in the literature suggest that etanercept is a safe option in the treatment of patients with rheumatoid arthritis and concurrent hepatitis C. We present three cases in which we have successfully used etanercept to treat psoriatic arthritis/psoriasis in patients with hepatitis C without worsening their hepatitis or interfering with their hepatitis treatment. With close monitoring of viral load and hepatic enzymes, etanercept may be a safe option for treating psoriatic arthritis/psoriasis in patients who also have hepatitis C.

Original language	English
Pages (from-to)	580-584
Number of pages	5
Journal	Journal of the American Academy of Dermatology
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/j.jaad.2004.05.013
State	Published - Oct 2004
Externally published	Yes

Access to Document

10.1016/j.jaad.2004.05.013

Cite this

@article{33c3b93bb5e24f8bab11fb935803edb8,

title = "Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases",

abstract = "Psoriasis and psoriatic arthritis are exacerbated by interferon alfa and other treatments for hepatitis C virus infection. Immunosuppressants and hepatotoxic drugs are relatively contraindicated in hepatitis C. Data in the literature suggest that etanercept is a safe option in the treatment of patients with rheumatoid arthritis and concurrent hepatitis C. We present three cases in which we have successfully used etanercept to treat psoriatic arthritis/psoriasis in patients with hepatitis C without worsening their hepatitis or interfering with their hepatitis treatment. With close monitoring of viral load and hepatic enzymes, etanercept may be a safe option for treating psoriatic arthritis/psoriasis in patients who also have hepatitis C.",

author = "Magliocco, {Melissa Amy} and Gottlieb, {Alice Bendix}",

year = "2004",

month = oct,

doi = "10.1016/j.jaad.2004.05.013",

language = "English",

volume = "51",

pages = "580--584",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection

T2 - Report of 3 cases

AU - Magliocco, Melissa Amy

AU - Gottlieb, Alice Bendix

PY - 2004/10

Y1 - 2004/10

N2 - Psoriasis and psoriatic arthritis are exacerbated by interferon alfa and other treatments for hepatitis C virus infection. Immunosuppressants and hepatotoxic drugs are relatively contraindicated in hepatitis C. Data in the literature suggest that etanercept is a safe option in the treatment of patients with rheumatoid arthritis and concurrent hepatitis C. We present three cases in which we have successfully used etanercept to treat psoriatic arthritis/psoriasis in patients with hepatitis C without worsening their hepatitis or interfering with their hepatitis treatment. With close monitoring of viral load and hepatic enzymes, etanercept may be a safe option for treating psoriatic arthritis/psoriasis in patients who also have hepatitis C.

AB - Psoriasis and psoriatic arthritis are exacerbated by interferon alfa and other treatments for hepatitis C virus infection. Immunosuppressants and hepatotoxic drugs are relatively contraindicated in hepatitis C. Data in the literature suggest that etanercept is a safe option in the treatment of patients with rheumatoid arthritis and concurrent hepatitis C. We present three cases in which we have successfully used etanercept to treat psoriatic arthritis/psoriasis in patients with hepatitis C without worsening their hepatitis or interfering with their hepatitis treatment. With close monitoring of viral load and hepatic enzymes, etanercept may be a safe option for treating psoriatic arthritis/psoriasis in patients who also have hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=4644274040&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2004.05.013

DO - 10.1016/j.jaad.2004.05.013

M3 - Article

C2 - 15389194

AN - SCOPUS:4644274040

SN - 0190-9622

VL - 51

SP - 580

EP - 584

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 4

ER -

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases

Abstract

Access to Document

Fingerprint

Cite this